Personalized medicine will improve heath outcomes and patient satisfaction. However, implementing personalized medicine based on individuals' biological information is far from simple, requiring genetic biomarkers that are mainly developed and used by the pharmaceutical companies for selecting those patients who benefit more, or have less risk of adverse drug reactions, from a particular drug. Genome-wide Association Studies (GWAS) aim to identify genetic variants across the human genome that might be utilized as genetic biomarkers for diagnosis and prognosis. During the last several years, high-density genotyping SNP arrays have facilitated GWAS that successfully identified common genetic variants associated with a variety of phenotypes. However, each of the identified genetic variants only explains a very small fraction of the underlying genetic contribution to the studied phenotypic trait. The replication studies demonstrated that only a small portion of associated loci in the initial GWAS can be replicated, even within the same populations. Given the complexity of GWAS, multiple sources of Type I (false positive) and Type II (false negative) errors exist. The inconsistency in genotypes that caused either by the genotypeing experiment or by genotype calling process is a major source of the false GWAS findings. Accurate and reproducible genotypes are paramount as inconsistency in genotypes can lead to an inflation of false associations. This article will review the sources of inconsistency in genotypes and discuss its effect in GWAS findings.
INTRODUCTION

Personalized Medicine
The term "personalized medicine" was first used some 13 years ago [1] in the context widely understood today of "the right drug for the right patient with the right dose at the right time through the right route". A more comprehensive definition comes from the President's Council of Advisors on Science Technology (PCAST): "'Personalized medicine' refers to the tailoring of medical treatment to the individual characteristics of each patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease or their response to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not [2] ." The definition does not encompass designing drugs for sensitive subpopulations, a goal that may remain elusive absent the support and incentives for those who would carry out the requisite research and development.
A rapid increase in published articles referring to personalized medicine as shown in Figure 1 is a testament to the significant and increasing scientific interest [3] that is driven by real medical needs and fostered by rapid advances in high density molecular technologies. The trend also reflects that personalized medicine has evolved from futuristic to the here and now, and portends that it will be a predominant challenge for the pharmaceutical industry and regulatory science in the current century.
There is no doubt that personalized medicine will improve heath outcomes and patient satisfaction. However, implementing personalized medicine based on individuals' biological information is far from simple, requiring translating scientific discoveries into therapies as well as fully applying scientific knowledge to ensure safety [4] . The pathway to bringing the safe therapies to the bedside and transforming clinical practice is a wide range of new biomarkers useful for prediction, diagnosis and prognosis. Biomarkers can be any specific and sensitive measures to reflect diseases or states of diseases for diagnosis, for predicting responses to drugs, and for disease monitoring during a therapy. They can be used as surrogate endpoints in clinical practices and in drug development, or as components integrated in diagnostic tools for personalized therapeutics.
According to the NIH Biomarkers Definitions Working Group, a biomarker is "a characteristic that is objecttively measured and evaluated as an indicator of normal biological processes, pathogenic processes or a pharmacological response to a therapeutic intervention [5] ." This broad definition encompasses biomarkers used in diagnostic tests and any other measurement of a person's health status or response to drugs. The discussion of biomarkers in this review will be constrained to molecular biomarkers, which are defined to be a molecule or set of DNA, RNA, protein or metabolite molecules that can be measured and used as biomarkers for purposes such as assessment of clinical responses, identification of risks, or selection of doses and patients in drug development and clinical practices [6] .
The use of molecular biomarkers in clinical practices, drug development, regulatory decision making, and postmarket surveillance can facilitate the development of safer and more effective medicines and enhance the benefit-risk profile of approved drugs and the implementation of personalized medicine. In the past two decades, advances in the development of molecular biomarkers have been made primarily by the pharmaceutical companies and academic institutions. Many of the molecular biomarkers have evolved as supportive evidence in proof-of-concept studies, but have not been further utilized to support regulatory apprsoval of drug products. However, some molecular biomarkers, including variations in DNA, alterations in the levels of genes expressed and functional proteins, have been successfully used in support of drug approval by the FDA and in clinical practices.
Genetic Biomarkers for Personalized Medicine
DNA is the genetic code used in the development and functioning of all mammals. Variations in DNA sequences (genetic variations) are the polymorphisms in a population or species caused by chromosome crossovers, genetic mutations, genetic drift, including single nucleotide polymorphisms (SNP), mutations, differences in copy number, insertions, deletions, duplications, and rearrangements. A SNP, the most common polymorphism, is a single base mutation at a specific genomic locus. It consists of two alleles, where the rare allele frequency is at least 1%. Inter-individual variations in the DNA sequences can be related with how humans develop diseases and respond to drugs. These genetic variations, in turn, can be used for discovery and validation of biomarkers for personalized medicine. Genetic biomarkers are mainly developed and used by the pharmaceutical companies for selecting those patients who benefit more, or have less risk of adverse drug reactions (ADRs), from a particular drug. Some of the genetic biomarkers currently on the market are used to personalize therapy. For example, human leukocyte antigen (HLA) allelic marker, HLA-B*5701, is a genetic biomarker that can be used to predict increased risk to develop abacavir-associated hypersensitivity reactions. Thus, it is recommended that its presence is assessed in patients with human immunodeficiency virus (HIV) prior to treatment with the antiretroviral drug, abacavir [7] [8] [9] . An example of how genetic biomarkers might prove useful for drug safety is the investigation of genes that encode proteins such as the cytochrome P450 enzymes that are responsible for metabolizing exogenous toxicants such as drugs. Genetic polymorphisms are prevalent in these enzymes. Gene deletions, missense, nonsense, and splice-site mutations can abolish enzyme activity, whereas mutations causing amino acid substitutions can lead to markedly modified enzyme action.
A good example is the anticoagulant warfarin that is a drug for preventing blood clots. Individual response to warfarin varies so greatly that patients have to be closely monitored to adjust the dose during treatment to prevent hemorrhage that can result in fatal strokes, etc. Warfarin is mainly metabolized by enzyme CYP2C9 that exhibits wide genetically-based activity variation among patients [10, 11] . Vitamin K epoxide reductase (VKORC1) is the target of this drug. Genetic variations of VKORC1 gene account for some of the dosing variation between individuals. To reach safe therapeutic levels, some haplotype groups require larger doses while other haplotype groups require lower doses. Studies are underway to identify if genotyping patients for CYP2C9 and for VKORC1 polymorphisms can reduce the risk of adverse events and save money [12] .
Another example of biomarkers enabling personalized medicine is the genetic testing of mutations in the KRAS gene (Kirsten ras) that cause lack of response to panitumumab and cetuximab in patients with metastatic colorectal cancer. KRAS is a protein that in humans is encoded by the KRAS gene [13] . While the protein product of the non-mutated KRAS gene performs an essential function in normal tissue signaling, the mutated KRAS genes are potent oncogenes that play a role in many cancers [14] . Recently, genetic studies revealed that the presence of mutations in the KRAS gene was associated with the response to panitumumab or cetuximab therapy in patients with colorectal cancer. The US Food and Drug Administration (FDA) accordingly updated the labels of these two anti-epidermal growth factor receptor (EGFR) antibody drugs, cetuximab (Erbitux ® ) and panitumumab (Vectibix ® ), incorporating information about testing for KRAS gene for mutations when treating for metastatic colorectal cancer. Testing allows physicians to rule out Erbitux ® and Vectibix ® as an option for patients with mutated KRAS tumors, avoiding unnecessary treatments in patients who are unlikely to benefit.
A germline mutation is a genetic change in the lineage of germ cells and can be transmitted to offspring, while a somatic mutation is a genetic variation that neither inherit from ancestor nor pass to offspring. Somatic mutations can occur in any types of cells except the germ cells (sperm and egg) and can (but do not always) cause cancer or other diseases and different responses to drugs. Table 1 lists the genetic biomarkers mentioned in some drug labels approved by the FDA. All but the last are SNPs. However, interest and research are increasing for other DNA variants such as insertions and deletions as well as copy number variations.
GWAS for Discovery of Genetic Biomarkers
GWAS History
In GWAS, genetic variants (SNPs) associated with phenotypic traits such as disease status and drug response are identified through comparing case and control populations. In 1996, Lander proposed the common disease, common variant model [15] . Based on both theoretical To conduct a GWAS, both a map of all possible common genetic variants of human and a technology for massive parallel measurements of these variants are required. Millions of common SNPs in human populations were determined and a genome-wide map of SNP-tagged haplotypes was derived from the SNPs by the International HapMap project [16, 17] . Concurrently, highthroughput SNP genotyping technology has advanced dramatically and now scientists can simultaneously interrogate hundreds of thousands of SNPs. GWAS has become a feasible and promising research field for exploring associations between genetic variations and health outcomes.
In 2005, the first GWAS was published in which a functional SNP in the complement factor H was identified to be associated with age-related macular degeneration [18] . Since then, GWAS has been successfully applied to identify genetic variants associated with a variety of phenotypes .
GWAS Workflow
In a GWAS, markers across the genomes (complete sets of DNA) of many individuals are interrogated to find the associations between genetic variations and the disease for developing better strategies to detect, treat and prevent the disease. A GWAS is a complicated process depicted in Figure 2 . There are a few excellent review articles that describe each step in a GWAS in great detail [40] [41] [42] .
To carry out a GWAS, a case-control design is typically used: people with the phenotypic trait being studied and normal individuals. A DNA sample from each participant is obtained, usually from blood, purified, and placed on a small chip and measured on a machine automatically. In this way, each participant's genome is interrogated for strategically selected genetic markers (SNPs). Thereafter, the raw data are used for determining genotypes of SNPs using a genotype calling algorithm. By comparing the genotypes, the SNPs with significantly different genotype frequencies between cases and controls are identified to be associated with the disease in study. However, the associated SNPs themselves may not directly cause the disease. Often, additional steps are needed to determine the causal genetic variation of the disease.
Sources of Inconsistency in Genotypes
The basis of GWAS is the hypothesis common traitcommon variant: the genetic architecture of complex traits comprises many common alleles, each of which could contribute a small risk to the individual [43] . The probability of identifying a significant SNP association is low. Therefore, a large number of samples are needed to achieve adequate statistical power. In addition, accurately determining genotypes is a crucial requirement for reliability of GWAS findings. Given the complexity of a GWAS and the huge amount of data generated, multiple sources of inconsistency in genotypes exist. The inconsistency in genotypes caused in the genotyping experiment or in the genotype calling process is one of the most important factors that introduce both Type I and Type II errors in GWAS. Table 2 lists the potential sources of inconsistency in genotypes.
INCONSISTENCY IN GENOTYPES
Genotyping Experiments
Consistency in genotypes is important for GWAS because inconsistency in genotypes can lead to spurious genetic associations. Repeatability and reproducibility of genotyping experiments are the measurements of consistency in the genotypes that can be determined from the experiments. Low repeatability and reproducibility in genotyping experiments diminish the accuracy of genotypes and may inflate the Type I and Type II error rate in GWAS.
Reproducibility of Genotyping Platforms
A fundamental component of a GWAS is the platform (Figure 2 ) that is used to interrogate genotypes of SNPs of patients and control subjects. Errors generated in genotyping, especially if they are distributed differenttially between patients and controls, are potential sources of spurious associations in GWAS findings. Many difficulties exist for correcting or reducing errors or biases introduced in genotyping experiments.
The debates about SNP selection [44, 45] that domi- Table 2 . Potential sources of inconsistency in genotypes.
Step in GWAS Potential sources
Genotyping platforms Experiment
Generations of a genotyping platform
Genotype calling algorithms
Parameter settings of a calling algorithm Genotype calling Genotype calling batch effect nated the early discussions on GWAS are now mostly resolved and simplified to the choice of genotyping platforms, mainly between the two leaders, Affymetrix and Illumina. Despite the fact that these two offer similar coverage of common variants in the HapMap [41] , differences in SNP coverage between Affymetrix and Illumina exist and are a potential source of Type II errors (losing significant associations). Since the designs of probe sets on SNP arrays, as well as the experimental protocols, are quite different between these two platforms, the consistency of common SNPs interrogated in both platforms is vital for obtaining reliable GWAS results. This type of inconsistency may cause both Type I errors and Type II errors in GWAS [46] . Evaluation of variations between platforms has been reported [47] and is expected to be thoroughly assessed in the future.
We examined the reproducibility of genotyping technology using two platforms, Affymetrix SNP array 6.0 (called Affy6 hereafter) and Illumina 1MDuo chip (called Illu1M hereafter), by assessing the consistency in genotypes between technical replicates of six subjects assayed in the same laboratories. DNA samples for the three HapMap subjects (NA10385, NA12449, and NA12448, coded as A, B, and C, respectively, in this review) are from a trio and were obtained from the HapMap consortium. The DNA samples of another three subjects (coded as D, E, and F in this review) are extracted from anonymous human liver specimens and were obtained from the US Cooperative Human Tissue Network (CHTN).
To measure genotyping reproducibility, genotype concordances were calculated for all pair-wise comparisons between the technical replicates of the DNA samples from six subjects for each genotyping site. Heatmaps of results for Affy6 from three laboratories and for Illu1M from two laboratories are shown in Figures 3 and 4 , respectively. The concordances between technical replicates of DNA samples from the same subject within a genotyping platform and within a genotyping laboratory are greater than 99%. The averaged intra-platform and intra-laboratory genotype concordances for Affy6 are 99.04%, 99.48%, and 99.69% for genotyping Lab-1, Lab-2 and Lab-3, respectively, for an average of 99.40% with a standard deviation of 0.29%. Concordances for Illu1M are 99.90% and 99.85% for genotyping sites Lab-1 and Lab-2, respectively, for an average of 99.87% with a standard deviation of 0.10%. Therefore, high intra-platform and intra-laboratory genotyping reproducibility is observed by using technical replicates. 
Inconsistency between SNP Arrays
Consistency in genotypes between different generations of the same genotyping platform is another concern and remains a challenge for GWAS. Different generations of genotyping platforms from both Affymetrix and Illumina have been delivered to the market and used in GWAS. For example, the Affymetrix GeneChip Human Mapping 500K array set (called Affy500K hereafter) has been used in published GWAS [32, 48, 49] , but later Affymetrix released the Affy6 to the market. As it is important to know whether genotypes determined with these two generations of SNP array are the same, we evaluated their consistency [47] .
Genotypes of common SNPs were interrogated in both Affy500K and Affy6 SNP arrays using the 270 HapMap samples and were determined using the same calling algorithm, Birdseed. There are 482,215 SNPs common to both arrays. The scatter-plot in Figure 5 (a) compares the missing call rates per SNP (percentage of SNPs that are not assigned to one of the three genotypes: homozygote, heterozygote, and variant homozygote) in the Affy500K (x-axis) and in the Affy6 (y-axis). Each of the points represents one of the common SNPs. When a SNP is located on or near the diagonal line, it indicates that the missing call rate for the SNP is consistent between the Affy500k and the Affy6. From Figure 5(a) , it can be seen that a large number of SNPs are not consistent in the missing call rates, some of which are very different between these two arrays. The scatter-plot in Figure 5(b) depicts the missing call rates of the 270 HapMap samples based on the common SNPs in the Affy500K (x-axes) and Affy6 (y-axes) arrays. From Figure 5(b) , it can be seen that the inconsistencies in missing call rates per sample are much smaller than the missing call rates per SNP (Figure 5(a) ). Moreover, it is observed that the missing call rates from the newer-generation Affy6 array are slightly lower than the missing call rates from the 
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older-generation Affy500K array. The p-values of a paired two-sample t-test for comparing the missing call rates per SNP (Figure 5(a) ) and missing call rates per sample (Figure 5(b) ) are 0 and 5.057 × 10 −60
, respectively, indicating that the difference of missing call rates per SNP and per sample between the Affy500K and the Affy6 are statistically significant.
Genotype Calling
In GWAS, a genotype-calling algorithm assigns genotypes for SNPs from the raw intensity data prior to downstream association analysis for identifying associated genetic variants. It is vital to know how reliable are the genotypes determined by the genotype calling process for assessing the utilization of GWAS findings.
Inconsistency between Calling Algorithms
Many genotype calling algorithms have been developed. Thus, it is important to know how consistent are the genotypes determined by using the different genotypecalling algorithms, though each of the algorithms reported a high successful call rate and accuracy. We evaluated inconsistency in genotypes determined using three genotype calling algorithms (DM, BRLMM, and Birdseed) that were released along with three generations of SNP arrays from Affymetrix [47] .
Raw data (CEL files) for the 270 HapMap samples were downloaded from the International HapMap project website (www.hapmap.org/downloads/raw_data/affy 500k/). These CEL files correspond to the Affy500K array. The file format is described on Affymetrix's developer pages (www.affymetrix.com/support/developer/ fusion/file_formats.zip). The chip description files (cdf) for both Nsp and Sty chips in the Affy500K and the files for annotating SNPs on chromosome X were also used when calling genotypes. They were downloaded from the Affymetrix website. The training set for using Birdseed on the Affy500K data was downloaded from the Broad Institute: www.broad.mit.edu/mpg/birdsuite/birdseed html.
Before calling genotypes, the quality of the raw data was assessed. All genotype calling by DM, BRLMM, and Birdseed reported in this review were conducted using apt-probeset-genotype of APT. The function apt-probeset-genotype enables many parameters to be changed by a user for each of the algorithms. The default values recommended by Affymetrix were used for all parameters.
The missing call rates per SNP and per sample were compared. Different missing call rates for many SNPs and samples were observed between the three algorithms. Furthermore, DM (single-chip based algorithm) has higher missing call rates compared to BRLMM and Birdseed (multiple-chip based algorithms). However, the inconsistency between BRLMM and Birdseed is much smaller. The paired two-sample t-test was used to test if the call rates per SNP and per sample are significantly different between the three algorithms. The calculated p-values are listed in Table 3 . They are less than 0.05 and thus the missing call rates are significantly different among the three algorithms. Table 4 gives the consistency in genotypes between the three genotype calling algorithms. 538,774 (0.41%), 285,788 (0.21%), and 200,592 (0.15%) genotypes are different between DM and Birdseed, between Birdseed and BRLMM, and between DM and BRLMM, respectively. Figure 6(a) compares the concordance of genotypes between BRLMM and Birdseed stratified on three genotypes. The concordance for homozygous calls is higher than for heterozygous calls. Moreover, discordance between heterozygous and homozygous genotypes is higher than that between the two homozygous genotypes. The same comparisons between DM and Birdseed and between DM and BRLMM are shown in Figure 6 (b) and 6(c), respectively. The similar trends are observed: homozygous calls being more consistent than heterozygous calls.
Genotype Calling Parameter Setting
Genotype-calling usually requires many user-specified parameters be adjusted for a particular algorithm. For example, it should be decided a) whether normalization is conducted before a genotype-calling algorithm is applied to determine genotypes based on the intensity data, and b) which normalization method, if required, should be used. There are also many algorithm-specific parameters that need to be set. BLRMM first derives an initial guess for each SNP's genotype using the DM algorithm [50] and then analyzes across SNPs to identify cases of non-monomorphisms. Thereafter, a prior distribution for cluster centers and variance-covariance matrices is estimated using the non-monomorphism SNPs. The prior distribution information of the SNPs and the clusters and variances of the initial genotype guesses are combined using a Bayesian procedure to calculate a posterior of cluster centers and variances. Genotypes of other SNPs are determined based on their Mahalanobis distances from the three cluster centers. Therefore, the parameters that specify the p-value cutoff for DM algorithm to include SNPs (default is set to 0.17) and the number of SNPs to be used (default is set to 10,000) affect the prior distribution.
Different parameter values may cause inconsistent genotypes called. We investigated the effect of changing confidence threshold in the genotype-calling algorithm BRLMM [51] .
The comparisons of missing call rates per SNP (Figure 7(a) ) and per sample (Figure 7(b) ) demonstrate that inconsistent genotype calls were generated from the same raw data when using BRLMM at confidence thresholds of 0.17, 0.30, 0.45, and 0.60 on the dataset of 270 HapMap samples. The Pearson-correlation coefficients of the corresponding comparisons are given at the top of the scatter plots. T-tests were performed to determine whether two sets of missing call rates from a normal distribution could have the same mean when the unknown standard deviations are assumed equal. The resulting p-values for the comparisons are less than 0.0001, indicating that missing call rates per sample and per SNP are statistically different. Furthermore, the inconsistency (defined as 1 -r) of missing call rates are positively related to the corresponding differences between the thresholds used, and negatively related to the sum of thresholds of the compared calling experiments (Figure 8) . BRLMM (c) ). The discordant successful genotype calls between two algorithms are depicted in the right panels of (a)-(c) (right y-axes) [47] . 
Batch Effect in Genotype Calling
A GWAS normally requires a large number of samples to attain needed statistical power, and thus entails analyses of thousands of raw data files (i.e., CEL files). The raw data size of one sample is tens of MB. It is difficult, if not impossible, to determine the genotypes of SNPs of all samples of a GWAS in one single batch on a single computer. The samples are usually divided into many batches for genotype calling. The variation in ways to divide samples into different batches for genotype calling potentially causes disparities in called genotypes that, in turn, causes spurious associations in GWAS results. We assessed the effects of changing the number and specific combination of CEL files in batches on genotypes called by using the 270 HapMap samples and the calling algorithm BRLMM [52] . Three genotype calling tests were conducted to assess the batch size effect. In the first test (BS1), the 270 HapMap samples were divided into three batches based on their population groups: 90 Europeans, 90 Asians, and 90 Africans. The genotypes were called separately by BRLMM using the default parameter setting suggested by Affymetrix. The second test (BS2) used a batch size of 45 samples. Genotypes were called from the CEL files from 90 European samples in two batches, each with 45 CEL files using BRLMM with the same parameter settings as in the first test. The same approach was applied to the Asian and African samples. In the third test (BS3), the batch size of 30 samples was used for each population group.
The effect of batch size on inconsistency in genotypes is based concordances of genotypes called between tests with different batch sizes as given in Table 5 . Batch size affects genotypes called. The heterozygous genotype concordance is considerably more affected than the homozygous genotype concordance.
Given that batch size affects genotypes called, the selection of samples (CEL files) to be placed in each batch can also be anticipated to alter genotype calling. The term batch composition effect is used here to denote the selected CEL files within batches. BRLMM with default parameter setting and the CEL files of 270 HapMap samples were used to evaluate the batch composition effect. In the first test (BC1), the 270 samples were placed in three batches. One batch contained 90 samples from the same population group, Europeans, Asians, or Africans. In the second test (BC2), the 90 samples in each of the three population groups were evenly divided into two subgroups with each subgroup having 45 unique samples. Genotype calling was then conducted in three batches with composition of: 1) subgroup 1 of Europeans + subgroup 1 of Asians, 2) subgroup 2 of Europeans + subgroup 1 of Africans, and 3) subgroup 2 of Africans + subgroup 2 of Asians. In the third test (BC3), the 90 samples in each of the three population groups were evenly divided into three subgroups with each subgroup having 30 unique samples. Genotype calling was then conducted in three batches with composition of: 1) subgroup 1 of Europeans + subgroup 1 of Asians + subgroup 1 of Africans, 2) subgroup 2 of Europeans + subgroup 2 of Asians + subgroup 2 of Africans, and 3) subgroup 3 of Europeans + subgroup 3 of Asians + subgroup 3 of Africans.
The batch composition effect on genotypes called is based concordances of genotypes called between tests with different batch compositions as given in Table 6 . Batch composition affects the genotypes called. Furthermore, the effect on heterozygous genotypes is considerably larger than for homozygous genotypes, since the concordance for heterozygous genotypes is lower than the corresponding concordance for homozygous genotypes.
IMPACT OF INCONSISTENCY IN GENOTYPES
The objective of GWAS is to identify associated genetic markers. It is critical to evaluate whether and how inconsistency in genotypes impacts the significant SNPs identified in the downstream association analysis.
Discordant Genotypes Generated in Genotyping Experiment Affect GWAS Findings
Inconsistency in genotypes generated in genotyping experiment could be considered small. However, since most genetic markers identified in GWAS confer very small relative risks, a very small error in genotyping could inflate in GWAS, resulting false associations.
To assess the effect of discordant genotypes on the associated SNPs identified in GWAS, simulations were conducted to estimate the effect of discordant genotypes on the associated SNPs identified in GWAS. First, a data set with a case population of 5000 samples and a control population of 5000 samples was generated in which the same minor allele frequency was applied to the case and control populations separately. Thus, the original data had an odds ratio of exactly one. Thereafter, a fixed concordant rate in genotypes was randomly applied to the data set and an odds ratio was calculated on the simulated data. The process was repeated 50,000 times for a pair of minor allele frequency and concordant rate. Therefore, 50,000 odds ratio values were obtained for a pair of minor allele frequency and concordant rate. Then, minor allele frequency and concordant rate were changed from 0 to 0.4 and from 1.00 to 0.94 in steps of 0.01 and 0.001, respectively. In the similar way, 50,000 odds ratios were simulated for each of all of the combinations of minor allele frequency values and concordant rates. Figure 9 shows the simulation results. The odds ratios are not caused by differences in minor allele frequencies for control and case populations in the simulations but Figure 9 . Results of simulating the effect of inconsistency of genotypes on the significant genetic biomarkers identified in GWAS. Odds ratios were simulated for 50,000 times for each pair of a genotype concordance (from 0.94 to 1.00 with a step of 0.001) and a minor allele frequency (MAF from 0.01 to 0.40 with a step of 0.01) by using a case population of 5000 samples and a control sample size of 5000 samples. Relationship between top 5% the 50,000 odds ratio values, concordance in genotypes, and minor allele frequency is depicted in (a). The intersection curves at minor allele frequency values 0.05, 0.10, and 0.20 are shown in (b).
are caused by inconsistency in genotypes simulated. Figure 9(a) gives the top five percentile values of the odds ratios and Figure 9(b) plots the relationship between the five percentile odds ratio and concordance in genotypes for some fixed minor allele frequency values. The trend is obvious in which the smaller the minor allele frequency and the larger the inconsistency in genotypes (the lower the consistency in genotypes), the larger the spurious (simulated) odds ratio. Therefore, the results demonstrate that a very small inconsistency in genotypes could substantially change odds ratios of genetic markers and thereby alter the final GWAS findings.
Propagation of Inconsistency of Calling Algorithm to Associated SNPs
To assess propagation of the inconsistency in genotypes determined by different calling algorithms to the signifycant SNPs identified in the downstream analysis in GWAS, three case-control mimics based association analyses were conducted for each of the sets of genotypes obtained using calling algorithms DM, BRLMM, and Birdseed. These analyses used 270 HapMap samples interrogated using the Affy500K (see section 2.2.1 for details). The lists of SNPs significantly associated with the case-control mimics were compared between the three calling algorithms. The comparisons of the significant SNPs obtained from the one degree of freedom allelic association tests and the two degree of freedom genotypic association tests are given in Figures 10(a) and (b) , respectively. It is clear that, for all case-control mimics and for both allelic and genotypic tests, the inconsistency in genotypes between the three algorithms causes disparity among lists of significant SNPs. For example, 1593, 1349, and 1873 SNPs from DM, BRLMM, and Birdsee, respectively, are identified using genotypic association testing to be significantly associated with the mimic using European as "case" but not significant when the other two algorithms are used to genotype call these SNPs. These SNPs could be false positive associations when using one algorithm or true positive associations that may be lost when using the other two algorithms. There are 941 SNPs from both DM and BRLMM, 254 SNPs from both DM and Birdseed, and 9473 SNPs from both BRLMM and Birdseed that are significantly associated with the mimic using European as "case" by the same genotypic association testing but not significant for Birdseed, BRLMM, and DM, respectively. Therefore, these SNPs might be true positive associations that could be lost when using one calling algorithms or false positive associations when using the other two algorithms. The similar observations can be seen from Figures 10(a) and (b) for all allelic association and genotypic association analyses with the mimics using Asian or African as "case".
We examined in which procedure of the downstream analysis, the quality control (QC) or the statistical testing for association, the inconsistency in genotypes between the three algorithms propagates into, by tracing the whole process of the downstream analysis and identifying whether the inconsistent SNPs failed to pass the QC or the statistical testing.
For the SNPs that are identified as significant using one algorithms but not significant using the other two algorithms, the distributions of SNPs failed in QC and in statistical test for all the association analyses are shown in Figure 11 . QC is more affected by the SNPs missed from DM, while statistical testing for association contributes relatively more to the missed SNPs by BRLMM and Birdseed.
For the SNPs that are identified as significant using two algorithms but not significant using the other algorithm, the distributions of SNPs failed in QC and in statistical test for all the association analyses are given in Figure 12 . QC is more affected for the SNPs missed by DM and Birdseed, while statistical testing for association contributes relatively more to the SNPs missed by BRLMM.
Propagation of Algorithmic Parameter Effect to Associated SNPs
The comparisons of the significantly associated SNPs Figure 11 . Significant SNPs identified by one algorithm but not by the other two. The red bars (genotypic association tests) and the blue bars (allelic association tests) give the numbers of SNPs identified as significant in association tests by DM but not by BRLMM and Birdseed, the magenta bars (genotypic association tests) and the cyan bars (allelic association tests) represent the numbers of SNPs identified as significant in association tests by BRLMM but not by DM and Birdseed, and the yellow bars (genotypic association tests) and the green bars (allelic association tests) indicate the numbers of SNPs identified as significant in association tests by Birdseed but not by DM and BRLMM. In each group of bars (by color), the first bar is for the design using African as "case", the second using Asian as "case", and the third using European as "case". The percentages of the SNPs failed in QC among the totals are plotted in solid circles (for DM), solid diamons (for BRLMM), solid up-triangles (for Birdseed) and the ones that failed the association tests denoted by the empty shapes for the corresponding bars.
obtained from calling results with different parameter settings (see section 2.2.2 for detail) are given in Figure  13 . Threshold effect on genotype calling is propagated into the downstream association analyses since, for any statistical tests (genotypic: left column; allelic: right column) and case-control mimics (Asian as case: first row; European as case: second row; African as case: last row), there are discordances for the significantly associated SNPs identified between different thresholds. Interestingly, the mimic using African as "case" identified more significantly associated SNPs compared with the mimics using Asian or European as "case". Additionally, the significantly associated SNPs from the African mimic are less discordant than those from the Asian and European mimics when comparing between different parameter settings. This finding is related with genetic diversity of different population groups of the HapMap samples used: the African is more genetically distinct compared to the Asian and European. Therefore, inconsistency in genotypes might be more amplified in the significantly associated SNPs for weaker traits than for stronger traits. The traits of reported GWAS are usually much weaker compared with the population differences Figure 12 . Significant SNPs identified in two algorithms but failed in the other one. The red bars (genotypic association tests) and the blue bars (allelic association tests) give the numbers of SNPs identified as significant in association tests by BRLMM and Birdseed but not by DM, the magenta bars (genotypic association tests) and the cyan bars (allelic association tests) represent the numbers of SNPs identified as significant in association tests by Birdseed and DM but not by BRLMM, and the yellow bars (genotypic association tests) and the green bars (allelic association tests) indicate the numbers of SNPs identified as significant in association tests by DM and BRLMM but not by Birdsed. In each group of bars (by color), the first bar is for the design using African as "case", the second using Asian as "case", and the third using European as "case". The percentages of the SNPs that failed in QC among the totals are plotted in solid circles (for DM), solid diamond (for BRLMM), solid up-triangles (for Birdseed) and the ones that failed the association tests denoted by the empty shapes for the corresponding bars. of the HapMap samples. A smaller number of concordant significantly associated SNPs are expected in real GWAS.
Propagation of Batch Effect to Associated SNPs
To assess propagation of the batch effect to the downstream analysis in GWAS, association analyses on the genotypes determined by BRLMM with different batch sizes and compositions (see section 2.2.3 for detail) were conducted by using the same three case-control mimics: European versus Asian and African; Asian versus European and African; African versus Asian and European. Before association testing, low quality SNPs were removed by QA/QC. Venn diagrams in Figure 14 compare the SNPs significantly associated with the same population group in genotypic association test using the genotypes determined by BRLMM with different batch sizes and compositions. Figure 14 demonstrates that the batch size and composition effects on inconsistency in genotypes propagate The results using European as case; and the last row (e), (f): The results using African as case [51] .
The more homogeneity in the samples of the batches, the smaller the inconsistency in genotypes called and the more the common significantly associated SNPs identified in the downstream analysis. Thus, we suggest that genotype calling should be conducted using large and uniform batch sizes with high homogeneity of samples in the same batches.
into the downstream association analyses. Further examining the significantly associated SNPs common to the compared batch sizes and compositions observe that the larger the batch size differences, the fewer the common significantly associated SNPs; the larger the batch composition difference in genetic homogeneity, the fewer the common significantly associated SNPs.
In summary, batch size and composition affect inconsistency in genotypes called by using BRLMM and downstream analysis results in GWAS. The larger the batch size differences, the larger the inconsistency in genotypes called and the fewer the common significantly associated SNPs identified in the downstream analysis.
FUTURE PERSPECTIVES
GWAS, as well as the subsequent replication studies, have been used to identify and validate genetic variants associated with many phenotypic traits. However, these associated genetic variants tend to exhibit very small effects on the studied phenotypic traits and only explain a rather small portion of the heritability. Therefore, there is a long way to go before scientists approach complete understanding of mechanisms of complex phenotypic traits and dissect their genetic architecture.
In addition to many possible sources of spurious associations such as sample size and population stratification that have been investigated and discussed intensively, consistent genotypes are required for concordant GWAS results from different studies. However, inconsistency in genotypes generated in the genotyping experiment and in the genotype calling may cause both Type I and Type II errors. In our opinion, translation of GWAS findings to clinical practices and personalized medicine and nutriation remains a huge challenge. We still need to understand the potential spurious association results caused by inconsistency in genotypes and derive methods to decrease such inconsistency and consequential spurious associations.
Next-generation sequencing is fundamentally changing the way in which genomic information of individuals at the DNA level is being obtained for better understanding of the human genome [53] [54] [55] [56] [57] [58] . It is expected that the genotypes determined by using next-generation sequencing technologies are much more accurate than those obtained from the SNP array technology and thus the inconsistency in genotypes will be reduced, if not near elimination. Therefore, we can look to a brighter future wherein advances in genotyping technologies lead to improved consistency in genotypes that, in turn, lead to more reliable GWAS findings.
